Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Medical Industry Today.
Press releases published on June 9, 2025
Secura Bio Announces First Patient Dosed in Phase 3 TERZO Study of COPIKTRA® (duvelisib) in Relapsed/Refractory Nodal T-follicular Helper Cell Lymphoma
GlobeNewswire
·
June 9, 2025
SUMMERLIN, Nev., June 09, 2025 (GLOBE NEWSWIRE) -- Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that the first patient has been dosed in its Phase 3 TERZO …
Sagimet Biosciences to Host Virtual KOL Event, “A New Mechanism of Action in Treating Acne: Update on Positive Phase 3 Denifanstat Trial for the Treatment of Moderate to Severe Acne” on June 16, 2025
GlobeNewswire
·
June 9, 2025
SAN MATEO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced it will host a …
IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
GlobeNewswire
·
June 9, 2025
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, announced that Patient 009 in the Phase 1 trial of …
New Report Reveals Canadian Men Are Dying Too Young
GlobeNewswire
·
June 9, 2025
TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Movember – the world’s leading men’s health charity – has released the Real Face of Men’s Health Report (the report) detailing new findings on the state of men’s health in Canada. The report reveals that more than …
SEED Therapeutics Appoints Dr. Bill Desmarais as Chief Financial Officer and Chief Business Officer
GlobeNewswire
·
June 9, 2025
KING OF PRUSSIA, Pa., June 09, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. ("SEED"), a biotechnology company pioneering targeted protein degradation (TPD) through the discovery of innovative molecular glues and bifunctional degraders, today announced …
Un nouveau rapport révèle que les hommes canadiens meurent trop jeunes
GlobeNewswire
·
June 9, 2025
TORONTO, 09 juin 2025 (GLOBE NEWSWIRE) -- Movember, le plus important organisme caritatif mondial dédié à la santé masculine, a publié le rapport intitulé Le vrai visage de la santé masculine, qui présente les nouvelles conclusions sur l'état de la santé …
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i
GlobeNewswire
·
June 9, 2025
Placebo-subtracted mean weight loss up to 8.4% at Day 36 19-day observed half-life supports once-monthly dosing as monotherapy and potential first-in-category monthly GLP-1 + Amylin combination Well-tolerated with no safety signals Company to host …
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
GlobeNewswire
·
June 9, 2025
NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it has received a Refusal to File (RTF) letter …
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
GlobeNewswire
·
June 9, 2025
First consumer products roll out in Q3 2025, creating near-term revenue potential and marking a new chapter in Jupiter's evolution Jupiter, Florida, June 09, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), …
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
GlobeNewswire
·
June 9, 2025
Preclinical data highlighted JADE101’s femtomolar APRIL binding affinity, extended non-human primate half-life of approximately 27 days, and sustained IgA suppression In non-human primates, JADE101 showed a differentiated pharmacokinetic and …
TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
GlobeNewswire
·
June 9, 2025
- For the TransCon CNP treatment-naïve cohort, combination treatment resulted in mean annualized growth velocity (AGV) of 9.14 cm/year, with an improvement in mean ACH height Z-score of +0.53 over 26 weeks - For the TransCon CNP-treated cohort, combination …
Keros Announces Return of $375 Million in Excess Capital to Stockholders
GlobeNewswire
·
June 9, 2025
LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of …
Portage Biotech and Compedica Stock-for-Stock Exchange
GlobeNewswire
·
June 9, 2025
DOVER, Del., June 09, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company formed under the laws of the British Virgin Islands (“Portage”) announce that on June 5, 2025 Portage and Compedica Holdings …
Liver Canada delivers a wake-up call to Canada in new PSA
GlobeNewswire
·
June 9, 2025
TORONTO, June 09, 2025 (GLOBE NEWSWIRE) -- Liver Canada is confronting the silent epidemic of liver disease with a powerful new public service announcement (PSA) titled Wake-Up Call. The campaign seeks to challenge misconceptions and encourage proactive …
CancerVax Targets Liver Cancers to Further Showcase Flexibility of Its Universal Platform
GlobeNewswire
·
June 9, 2025
Lehi, Utah, June 09, 2025 (GLOBE NEWSWIRE) -- CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform designed to use the body’s immune system to treat cancer, today announced that it will expand its preclinical program to …
AB Science announces EMA approval of Masivet shelf-life extension to 4 years
GlobeNewswire
·
June 9, 2025
PRESS RELEASE AB SCIENCE ANNOUNCES EMA APPROVAL OF MASIVET® SHELF-LIFE EXTENSION TO 4 YEARS Paris, June 9, 2025, 8am CET AB Science SA (Euronext - FR0010557264 - AB) today announced that the European Medicine Agency (EMA) has approved the extension of the …
AB Science annonce l’approbation par l’EMA de la prolongation de la durée de conservation de Masivet à 4 ans
GlobeNewswire
·
June 9, 2025
COMMUNIQUE DE PRESSE AB SCIENCE ANNONCE L'APPROBATION PAR L'EMA DE LA PROLONGATION DE LA DURÉE DE CONSERVATION DE MASIVET® À 4 ANS Paris, 9 juin 2025, 8h AB Science SA (Euronext - FR0010557264 - AB) annonce aujourd'hui que l'Agence européenne des …
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
GlobeNewswire
·
June 9, 2025
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING Nantes, June 9th, 2025, 8 a.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) informs its shareholders and the market of the update on the terms of the Combined General Meeting scheduled …
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE
GlobeNewswire
·
June 9, 2025
MISE À JOUR DES MODALITÉS DE L’ASSEMBLÉE GÉNÉRALE Nantes, France, 9 juin 2025, 8 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), informe ses actionnaires et le marché de la mise à jour des modalités de l’Assemblée Générale Mixte …
Press Release: Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season
GlobeNewswire
·
June 9, 2025
Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season Paris, June 9, 2025. Sanofi is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025- …